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IGF 1,IGr I1 SERUM LCVELS IN UECKlJITII-I,lICDCMANN SYNDROME (OW).
Duplication of the llp15 region has bcer~ described in some patients with BU, also called Cxomphalos-Placroglossia Gigantism syndrome. IGF I1 gcne is localized at the llp15 region.
A markedly increased expression of IGF I1 gene was reporLed in 1,Iilm's tumour, the incidence of which is increascd in OW. These findings had led us to speculate for a possible overproduction of IGF I1 protein in this disorder. Using a specific binding assay (JCCM 1986 ) and a RIA for comparative dctcrmination of IGF I,we have measured the serum levels of 11 unrelated children (agcd from 1 month to 7 years) with 01.1. 4 had suecessivc invcstiqations. In 4 infants out of B bcforc 1 year, IGF I was more elevated than controls. An overgrowth was present in 3. In thc older children from one to seven years IGT I did not differ from normals. IGF I1 levcls werc similar to the con~rols whatever thc age. [loreoiler, in three children having developcd a tumour (ganglioncuroma n = 2, nephroblastoma n = 1) IGT riled consent 10 (GHD) chlldren uere tested during GH thera PY (phase 1) and after more than 6 weeks (phase 2 ) withdrawal . Glycemic response was normal In both situat lords, rnax.IR1 and c-p. were reduced as cornpared to age-ri~atched normal values 11-1 both phases. 1RI levels were slgnlf icantly higher in phase 1 than 2, but c-p. showed only a sl ight inslsnlf cati it Increase In the older age group. Insul in blndlr~g (7.5Xt-0.8 us .5.5 t-0.6 5.0. ) and aff 1-nity were reduced in phase 2. Comparable results of binding studles were obtained after. 7 days of GH-wlthdraual. Our results showed down-regulated receptors in phase I as evidence of permanentl:, increased ir!sul ln leuels. LJe conclude decreased hepatlc degradation under GH.
I.ic h.ive rneasurcd Ltx insulin rcsponse t u oral ]:lucose 1o:iding (1.75 ~, / k f i ) il 17 prepubertal and 20 pubertnl ciiildrcn 01 varying stature. All pulrcrtal children ucrc studied during the puLerLd1 growth spurt. Hcan (SEM) f;x,tiny, cancentrdtions were, baiore pubcrty, glucose 4.3 (0.1) nm.ol/l insuliri 4.5 (0.8) mU/l, and daring pubcrty, glucose 4.8 (0.1) na,ol/l, insulin 13.0 (1.7) niU/l (p<0.001). Thc irlcrense in fasting insulin concentr.ition during puberty was dccunlpnnied by e 10W, i n c r e n b e in the incrcnietitdl lnsulin responsv afLer glucusc. Ttic role of growth hornione (Gll) in inducing these changes was studied it, 16 tall cllildren (4 prc-pubertdl, 12 pubertal) who underwent 24 hour CH profiles. The increase i n Cll secretion associated with stngc 213 breast deueloplnenl wa:; .~ccompanied by a rise in likstinp, insul~n. Hcfore puberty thc surprned CtI pulsc iimplltude xi.,:: b8 (8.2) n,U/l/day with a Iutcnn I;isting insulin concentrntion u t 6.2 ( 2 . 7 ) nU/l; at bri,nst stage ;'I3 the prllsc zsylitudc $:as 205 (35.5) mU/llday a7.d insulin 15.9 (6.5) mU/l. In 14 cliildrcn receiving CII treatment tile mean fasting insulin concentration rose at one ycar of therspy: pre-trcdtacnt 4.8 (1.0) i#iU/l, 1 yedr 15.1, (2.1) mU/1; jr<0.001). Tall children hod highrr mean noccurn,il insulin concentrations than short children irrespcctivc oC pubcrtdl stayc.
There is a physiological in~rensc in serun insullil conccntmtion durlnp, puberty vl~~ch is probably secotldnry to r !~ rise in srrurn Cll conccntmtion. This has Important ~rn[rlicat~o!rs both i o r the nlrxlulation of rcajronsc to Cll and for Lhe man.igemfnt u i adolescent diabetics. ((21) n m b w iiv SIKXT CIIILIXW UnLil rfcatly, due LO tile linutnl (a1 sl~pply, QI Llrerapy Ims Imn uscd or~ly iri G I deficiency ((XI) . It has h n slloim that also other shorL dlildrcn m y kncl iL fro11 0 1 cherapy. UuL il~erc 1x1s Lxr.n no other m m s except Lrial to prdict tile reslurisc. TL has k~n slloim c,irlicr tililt Ulere is a rise in scrim PTIIIT concaLratla1 during (a1 therapy. To cvali~ltc Lhc vxlidity 0 1 . I'IIIJVI' detcnni~i,~Llori in the pmllction of the respnx LO ( : I 1 tl~crapy, wc follo~icd dlimges in 1 ' 1 IINI' for 6 mntlw afier tile onset. of GI1 Lrimtnmt. 'lhe stutly cin~priwzl 12 children, 5 luys and 7 girls,wilh the nn3n age of 8.%3.8(2.Gl6.8) and I~ne age 5.G3.7 (I .Z-13) years. In a1 1 I h c 1-elaL1ve I~cidlt ims Irlcw -2.SI). Nine idere diagi~ox~l (@< 01<7ug/l). 'llle duldrcn wcrc trealed r.iiti~ biosyriliicLic WI (proviili~l by Eli Lilly S.A.) ,given aL Iml-tuir',s.c. ,O.IU/kg/x3/id<. Ulml ~unples for I'IIINI' \>,ere idkcn n~ dg Lvld .IL 1 irk, 5 \rks, 3 and 6 mnlhs dudng the tiicrapy. 
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kONITORING GROWTH AND GROWTH HORMONE THERAPY BY SERUM bETERHINATION OF ANTIGENS RELATED TO THE AHINO-PERHINAL TYPE I11 PROCOLLAGEN PROPEPTIDE (P-111-NP) Serum P-111-NP reflects fibriliogenesis. To study whether P-III-NP can be used to monitor growth, it was determined by two different radioimmunoassays. One recognizes predominantly the intact triple-stranded propeptide showing a lesser affinity to the smaller monomeric peptide (RIAgnost), while the other detects both forms equally (FAB). In healthy children (n=375, aged 0 to 16 years) P-111-NP determined with either assay followed clnsely growth velocity. Patients with Turner's-Syndrome (n=ll: 17r4/90+ 22 (RIAgno?t/FAE! in ng/ml respectively)), constitutional short stature (n=16: 19+5/105+27) and growth hormone deficiency (GHD) (n=23: 16?8/82+_29) had low levels, while those with tall statllre (n=ll: 56+45/174+38) had high levels, which declined during estradiol-therapy in girls (n=S: 23+4/125?22). In GHD during recombinant growth hormone therapy (n=20) P-111-NP values increased after only 3 injections (~(0.01) and stayed elevated above baseline for 6 months (ms). Results were compared to-growth (median 5.6 cm (0.4 to 13.9) in 6 ms) and to established methods of growth monitoring (somatomedin C, alkaline phosphatase). P-111-NP (FAR) values correlated with the individual growth rates during the first (r=0.40; p(0.05) and the second ! ms (r=n.hh: p(0.001) and the total 6 ms periods (r=0.46 ~(0.05). All other parameters showed some association to growth only during one or two treatment periods. Thus, P-111-NP can be used for growth monitoring. 1 1 (1170-5120)l (9.6.-50) ((1.7-32.2) [(8.9-110.0) 
